Business Expanding LYMPHOGENiX Limited Establishes R&D Base in Nagoya, Aichi, Leveraging Lymphatic Regeneration Technology

LYMPHOGENiX Limited is a biotech startup founded in London, UK in 2024. The company focuses on lymphatic regeneration technology at its core and is engaged in therapeutic development centered on infertility, as well as research into applications across a broad range of disease areas including heart failure, pulmonary fibrosis, and skin aging. One of its distinguishing features is its novel approach to infertility treatment, which targets lymphatic function within the endometrium - an area that has not traditionally been the main focus of conventional therapies. The company also adopts a translational business model that spans both human healthcare and livestock applications.

To accelerate its research and development, the company established its Japanese subsidiary, LYMPHOGENiX Research Co., Ltd., in Nagoya, Aichi in April 2026, strengthening its collaborative research framework with academic institutions centered on Nagoya University. In establishing this base, JETRO’s Invest Japan Business Support Center (IBSC) provided comprehensive assistance, including business matching support, introductions to legal and administrative experts for company incorporation, and public relations support.

Looking ahead, the company is expected to strengthen the R&D infrastructure for regenerative medicine through collaboration with Japanese pharmaceutical companies and research institutions, while also expanding into the bioeconomy domain with potential applications in the livestock sector. These initiatives are anticipated to contribute to the advancement of international joint research in the life sciences and healthcare fields.